000170520 001__ 170520
000170520 005__ 20240229133715.0
000170520 0247_ $$2doi$$a10.1002/onco.13961
000170520 0247_ $$2pmid$$apmid:34476870
000170520 0247_ $$2ISSN$$a1083-7159
000170520 0247_ $$2ISSN$$a1549-490X
000170520 0247_ $$2ISSN$$a2159-8401
000170520 0247_ $$2altmetric$$aaltmetric:112800099
000170520 037__ $$aDKFZ-2021-01979
000170520 041__ $$aEnglish
000170520 082__ $$a610
000170520 1001_ $$0P:(DE-He78)ad44271ecf6b1eec3e0d0089c66dfdbe$$aChen, Li-Ju$$b0$$eFirst author$$udkfz
000170520 245__ $$aAssociation of polypharmacy with colorectal cancer survival among older patients.
000170520 260__ $$aHoboken, NJ$$bWiley$$c2021
000170520 3367_ $$2DRIVER$$aarticle
000170520 3367_ $$2DataCite$$aOutput Types/Journal article
000170520 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1642423927_14848
000170520 3367_ $$2BibTeX$$aARTICLE
000170520 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000170520 3367_ $$00$$2EndNote$$aJournal Article
000170520 500__ $$a#EA:C070#LA:C070#  /2021 Dec;26(12):e2170-e2180
000170520 520__ $$aIn geriatric oncology, polypharmacy is often assessed during a comprehensive geriatric assessment. Previous studies about its association with survival among colorectal cancer (CRC) patients were inconclusive and had high risk for indication bias.A cohort study was conducted with 3,239 CRC patients, aged ≥65 years, who were recruited in Germany between 2003 and 2016 while being hospitalized for CRC surgery. We defined polypharmacy as concurrent use of 5 or more drugs, and excessive polypharmacy (EPP) as concurrent use of 8 or more drugs. Cox proportional hazards regression models were performed to assess the associations of polypharmacy with 5-year overall (OS), CRC specific (CSS), and non-cancer specific survival (NCS) with rigorous adjustment for morbidity to minimize indication bias (e.g., for cancer stage, functional status, and 13 common diseases/conditions).The prevalence of polypharmacy was 54.7% and that of EPP was 24.2%. During up to 5 years of follow-up, 1,070 participants died among whom 615 died of CRC and 296 died of other causes than cancer. EPP was statistically significantly associated with poorer up to 5-year OS (hazard ratio (HR) [95% CI]: 1.23 [1.02-1.47]) and CSS (1.31 [1.03-1.68]). HR point estimate for NCS was higher than 1 (1.22) but not statistically significant.Polypharmacy was very common and EPP was a weak risk factor for mortality in this large cohort of older CRC patients. Clinical trials are needed to address the causality of this relationship because older CRC patients might benefit from de-prescribing drugs without an indication.The results of our study support the hypothesis that excessive polypharmacy, defined as use of 8 or more concurrently used active substances, has a negative impact on older colorectal cancer (CRC) patients' prognosis. Our study suggests to oncologists that performing a medication review for older CRC patients with 8 drugs or more is indicated (especially when a broader comprehensive geriatric assessment is being performed). Such a medication review should not only focus on reducing the number of medications (by de-prescribing drugs without an indication) but should also check the appropriateness of indicated drugs for older (cancer) patients.
000170520 536__ $$0G:(DE-HGF)POF4-313$$a313 - Krebsrisikofaktoren und Prävention (POF4-313)$$cPOF4-313$$fPOF IV$$x0
000170520 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo01.inet.dkfz-heidelberg.de
000170520 650_7 $$2Other$$aColorectal cancer
000170520 650_7 $$2Other$$aComprehensive Geriatric Assessment (CGA)
000170520 650_7 $$2Other$$aGeriatric Oncology
000170520 650_7 $$2Other$$aPolypharmacy
000170520 650_7 $$2Other$$aSurvival
000170520 7001_ $$0P:(DE-He78)abb10265fc5b7b424eee557e979d490f$$aNguyen, Thi Ngoc Mai$$b1$$udkfz
000170520 7001_ $$0P:(DE-He78)c259d6cc99edf5c7bc7ce22c7f87c253$$aChang-Claude, Jenny$$b2$$udkfz
000170520 7001_ $$0P:(DE-He78)6c5d058b7552d071a7fa4c5e943fff0f$$aHoffmeister, Michael$$b3$$udkfz
000170520 7001_ $$0P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2$$aBrenner, Hermann$$b4$$udkfz
000170520 7001_ $$0P:(DE-He78)c67a12496b8aac150c0eef888d808d46$$aSchöttker, Ben$$b5$$eLast author$$udkfz
000170520 773__ $$0PERI:(DE-600)2023829-0$$a10.1002/onco.13961$$gp. onco.13961$$n12$$pe2170-e2180$$tThe oncologist$$v26$$x1549-490X$$y2021
000170520 909CO $$ooai:inrepo02.dkfz.de:170520$$pVDB
000170520 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)ad44271ecf6b1eec3e0d0089c66dfdbe$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000170520 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)abb10265fc5b7b424eee557e979d490f$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000170520 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)c259d6cc99edf5c7bc7ce22c7f87c253$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000170520 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)6c5d058b7552d071a7fa4c5e943fff0f$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000170520 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2$$aDeutsches Krebsforschungszentrum$$b4$$kDKFZ
000170520 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)c67a12496b8aac150c0eef888d808d46$$aDeutsches Krebsforschungszentrum$$b5$$kDKFZ
000170520 9131_ $$0G:(DE-HGF)POF4-313$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vKrebsrisikofaktoren und Prävention$$x0
000170520 9141_ $$y2021
000170520 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bONCOLOGIST : 2019$$d2021-01-31
000170520 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2021-01-31
000170520 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2021-01-31
000170520 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central$$d2021-01-31
000170520 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2021-01-31
000170520 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2021-01-31
000170520 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2021-01-31
000170520 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2021-01-31
000170520 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2021-01-31
000170520 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bONCOLOGIST : 2019$$d2021-01-31
000170520 9201_ $$0I:(DE-He78)C070-20160331$$kC070$$lC070 Klinische Epidemiologie und Alternf.$$x0
000170520 9201_ $$0I:(DE-He78)C020-20160331$$kC020$$lC020 Epidemiologie von Krebs$$x1
000170520 9201_ $$0I:(DE-He78)C120-20160331$$kC120$$lPräventive Onkologie$$x2
000170520 9201_ $$0I:(DE-He78)HD01-20160331$$kHD01$$lDKTK HD zentral$$x3
000170520 980__ $$ajournal
000170520 980__ $$aVDB
000170520 980__ $$aI:(DE-He78)C070-20160331
000170520 980__ $$aI:(DE-He78)C020-20160331
000170520 980__ $$aI:(DE-He78)C120-20160331
000170520 980__ $$aI:(DE-He78)HD01-20160331
000170520 980__ $$aUNRESTRICTED